Report cover image

Needle Free Injections Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

Publisher GlobalData
Published Jul 16, 2024
Length 74 Pages
SKU # GBDT19099855

Description

Needle Free Injections Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update


Summary

GlobalData's Medical Devices sector report, “Needle Free Injections Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Needle Free Injections pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Needle-free Injections are the devices that do not use a needle to administer medication.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Needle Free Injections under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Needle Free Injections and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Needle Free Injections under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

74 Pages
    • Needle Free Injections Overview
    • Needle Free Injections - Pipeline Products by Stage of Development
    • Needle Free Injections - Pipeline Products by Territory
    • Needle Free Injections - Pipeline Products by Regulatory Path
    • Needle Free Injections - Pipeline Products by Estimated Approval Date
    • Needle Free Injections Companies - Pipeline Products by Stage of Development
    • Needle Free Injections - Pipeline Products by Stage of Development
    • aVaxziPen Limited Company Overview
    • Boston Scientific Corp Company Overview
    • Crossject SA Company Overview
    • Enable Injections Inc Company Overview
    • Eternity Healthcare Inc Company Overview
    • Inovio Pharmaceuticals Inc Company Overview
    • Medical International Technologies (Mit Canada) Inc Company Overview
    • PharmaJet Inc Company Overview
    • Teva Pharmaceutical Industries Ltd Company Overview
    • Jun 27, 2024: PharmaJet Needle-free System Selected for WHO Polio Immunization Campaign in Somalia
    • Jun 13, 2024: Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen (Patented Nicotinamide Riboside Chloride or Nrc)
    • May 30, 2024: Crossject Announces Publication of Clinical Data on Zepizure in Neurology and Therapy
    • May 08, 2024: Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
    • May 08, 2024: Teva Pharmaceutical Industries Reports Earnings Results for the First Quarter Ended March 31, 2024
    • May 07, 2024: Baxter to Present at Bank of America 2024 Health Care Conference
    • May 02, 2024: Crossject signs a geographic extension of ZEPIZURE commercialization agreement in Europe
    • Apr 25, 2024: Merck Announces First-Quarter 2024 Financial Results
    • Apr 24, 2024: Nature Publication Highlights the Benefits of Tropis Intradermal when used to Administer a First-In-Class Self-Amplifying MRNA Vaccine
    • Apr 23, 2024: ICU Medical Announces Time of First Quarter 2024 Earnings Conference Call
    • Apr 17, 2024: Carclo plc Welcomes New Board Member
    • Apr 10, 2024: Sichuan Kelun Pharmaceutical Reports Earnings Results for the Full Year Ended December 31, 2023
    • Apr 01, 2024: Industry Veteran Joins Merck as New EVP, Chief HR Officer
    • Feb 29, 2024: ICU Medical Board Member Resigns, Retires from Smiths Group
    • Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
    • Feb 28, 2024: Crossject Advances in its U.S. Strategy and Reports Financial Results for 2023
    • Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
    • Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
    • Feb 14, 2024: Enable Injections Announces Plans to Expand Manufacturing Facilities and Corporate Headquarters
    • Feb 08, 2024: Baxter Reports Fourth-Quarter and Full-Year 2023 Results
    • Feb 07, 2024: Terumo Announces Change of Executive Officers (PDF 232.27 KB)
    • Feb 01, 2024: Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
    • Jan 19, 2024: Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
    • Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
    • Jan 04, 2024: Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE
    • Jan 04, 2024: Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
    • Jan 03, 2024: Medytox Announces Executive Appointments in Luvantas, Inc
    • Dec 22, 2023: Crossject Signs Zepizure Commercialization Agreement for Northern Europe
    • Nov 28, 2023: Alchemy 43, Rapidly Expanding Aesthetics Brand, Now Offering GLP-1 Injections for Weight Management
    • Nov 07, 2023: Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
    • Nov 03, 2023: Jabil Reports Changes to Board of Directors
    • Nov 03, 2023: Jabil Announces Upcoming Changes to the Board of Directors
    • Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
    • Oct 03, 2023: Baxter Appoints Joel Grade Chief Financial Officer
    • Oct 02, 2023: Enable Injections Receives First U.S. Food and Drug Administration (FDA) Approval
    • Sep 28, 2023: Teva Announces Changes to Executive Management Team
    • Sep 19, 2023: Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors
    • Aug 21, 2023: Carclo Appoints Eric Hutchinson as New CFO
    • Aug 10, 2023: Medytox Appoints Director Kim Jae-wook to Oversee Medical Division
    • Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
    • Jul 12, 2023: Carclo Announces Unaudited Preliminary Results for the year ended 31 March 2023
    • Methodology
    • About GlobalData
    • Contact Us
    • Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.